Ind-Swift reports net loss of Rs 1.64 crore in Q1

16 Aug 2018 Evaluate

Ind-Swift has reported results for first quarter ended June 30, 2018.

The company has reported net loss of Rs 1.64 crore for the quarter under review as compared to net loss of Rs 14.56 crore for the same quarter in the previous year. However, total revenue of the company increased by 48.54% at Rs 80.67 crore for Q1FY19 as compared Rs 54.31 crore for the corresponding quarter previous year.

Ind-Swift manufactures and markets finished dosage forms, through their different divisions, focusing on the needs of various therapeutic segments. The divisions include the following: Super Speciality, Animal Division, Daignosis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×